Group 1 - Lin Hongjun has been appointed as the new general manager of Tianzhi Fund as of October 31, 2025, with a background in several prominent funds [1] - The number of fund managers in the active equity sector managing over 10 billion yuan has increased to 109, up by 34 from the previous quarter [2] - Central Huijin's holdings in ETFs have reached approximately 1.55 trillion yuan, an increase of over 200 billion yuan compared to the previous quarter [3] Group 2 - Fund manager Xie Zhiyu has increased his stake in Shuguang Shuchuang, with his funds holding 2.3496 million shares and 1.5845 million shares respectively as of the end of Q3 [3] - The market experienced a downturn, with the ChiNext index dropping over 2%, and the total trading volume in the Shanghai and Shenzhen markets was 2.32 trillion yuan, a decrease of 103.9 billion yuan from the previous trading day [4] Group 3 - The Chinese innovative drug industry is entering a new phase of global leadership, supported by comprehensive policy backing, transitioning from imitation to original innovation [7] - The newly launched fund "Fuguo Xinghe Mixed" is a mixed securities investment fund managed by Fan Yan, with a performance benchmark based on a combination of various indices [8]

Market Overview - The three major indices weakened, with the Shanghai Composite Index down 0.81% and the ChiNext Index down 2.31% [2] - The computing hardware industry chain showed a significant pullback, particularly in CPO and memory sectors, while AI applications, innovative pharmaceuticals, and consumer concepts performed strongly [2] - Approximately 3,800 stocks rose, with a total trading volume of 2.35 trillion yuan, a decrease of 114.5 billion yuan from the previous trading day [2] Monthly Performance - The Shanghai Composite Index increased by 1.85% for the month, briefly surpassing 4,000 points, marking a ten-year high, while the ChiNext Index fell by 1.56% [2] - The North China 50 Index performed well, with a monthly increase of over 3.5% [2] Market Sentiment - There is a noticeable divergence in performance between indices and individual stocks, with a significant number of stocks rising despite the overall index decline [2] - Recent trends indicate a shift from large-cap stocks to smaller-cap stocks, as investors seek opportunities in smaller, high-growth companies [4] Sector Performance - The WenDe Microcap Index has shown strong performance in November historically, with a cumulative increase of 77% year-to-date [8] - The Microcap Index has recorded positive monthly performance for ten consecutive months, indicating strong market expectations for the upcoming month [8] Investment Opportunities - Analysts suggest that the current market environment favors smaller stocks, particularly during the earnings vacuum period in November, which historically sees strong performance from micro-cap stocks [6] - The focus on innovative pharmaceuticals is heightened due to the introduction of a "commercial insurance innovative drug directory" mechanism in national negotiations [15] - AI applications are gaining traction, particularly with the release of OpenAI's Sora2 model, which enhances video creation capabilities and social media integration [16] Sector Highlights - The biotechnology sector showed strong gains, with biopharmaceuticals up 4.09% and innovative drugs up 3.35% [14] - The solid-state battery sector is expected to see growth due to advancements in technology and production requirements, presenting investment opportunities [17]

Core Viewpoint - The innovative drug sector in Hong Kong and A-shares has seen a significant rally driven by multiple favorable factors, including the introduction of a "commercial insurance innovative drug catalog" in national medical insurance negotiations [1][4]. Market Performance - A-share innovative drug stocks performed actively, with notable gains including: - Sanofi Guojian and Shuyai Shen both hitting the 20% daily limit up - Other stocks like Zhongsheng Pharmaceutical and Lianhuan Pharmaceutical also reaching their daily limits [1][2] - In the Hong Kong market, notable stocks such as Sanofi Pharmaceutical and Xinda Biopharmaceutical saw increases of nearly 12% and 8.49% respectively [2][3]. Policy Support - The introduction of the "commercial insurance innovative drug catalog" aims to alleviate the payment pressure for high-value innovative drugs and provide broader avenues for R&D returns [4]. - The recent guidelines from the Central Committee emphasize support for the development of innovative drugs and medical devices, reinforcing the policy foundation [5]. R&D and Collaborations - Leading companies are making substantial progress in international collaborations, with Sanofi Pharmaceutical registering two global Phase III clinical trials for its dual antibody drug SSGJ-707 [5]. - The innovative drug sector has seen a surge in licensing deals, with a reported 170% year-on-year increase in patent licensing transactions, exceeding $100 billion in 2025 [5]. Financial Performance - Major companies reported strong financial results: - WuXi AppTec's revenue reached 32.86 billion yuan, up 18.6% year-on-year - Hengrui Medicine reported a revenue of 23.188 billion yuan, up 14.85%, with a net profit increase of 24.50% [6]. - Positive macroeconomic signals include the U.S. decision to cancel additional tariffs on Chinese goods, which may benefit international collaborations for innovative drug companies [6]. Future Outlook - Analysts are optimistic about the continued growth of the innovative drug sector, with expectations of sustained policy support and enhanced global competitiveness for Chinese innovative drugs [7]. - The trend of declining interest rates by major central banks is anticipated to further boost the valuation of innovative drugs [7].

Market Overview - The market experienced a downward trend throughout the day, with all three major indices declining. The pharmaceutical sector showed resilience with an increase, while the software sector was active. Conversely, computing hardware and chip-related stocks faced collective declines [1]. ETF Performance - The Sci-Tech Innovation Drug ETF surged over 7%, indicating strong investor interest in the pharmaceutical innovation sector [1]. - Specific ETFs and their performance include: - Huatai-PineBridge Sci-Tech Innovation Drug ETF: 0.922, up 7.71% [2] - Guotai Junan Sci-Tech Innovation Drug ETF: 0.989, up 7.27% [2] - Hong Kong Stock Connect Innovation Drug ETF: 1.756, up 5.78% [2] - Other ETFs in the innovation drug category also showed positive performance, with increases ranging from 5.1% to 5.78% [2]. Industry Insights - Analysts suggest that China's innovative drug industry is integrating robustly into the global pharmaceutical innovation system. Over the past decade, the industry has shifted from a focus on generic drugs to a significant increase in business development (BD) transactions in global innovative drugs. This transition reflects a move from "following" and "keeping pace" to "leading" in certain areas, supported by policy, clinical breakthroughs, and capital [2].

10月31日，A股震荡走弱，截至收盘，沪指跌0.81%，深成指跌1.14%，创业板指下跌2.31%。 对于市场，华泰证券认为，上半周的上涨一定程度上是计入了对重大事件的较好预期，一旦落地或将引 发行情波动。东方证券则表示，"该涨不涨，该跌不跌"是市场目前主要特征，说明走势仍然健康，板块 之间轮动有序，为日后继续盘升蓄势。 盘面上，题材加速轮动，创新药等医药股午后持续反弹，舒泰神等多股涨停;影视传媒、游戏、Sora概 念等AI应用端集体走强，三六零等多股涨停;白酒等消费股概念拉升，中锐股份2连板;锂电等新能源赛 道上扬，天际股份2连板;福建板块再度走强，平潭发展斩获11天8板;此外，人形机器人、免税等板块盘 中均有所表现。下跌方面，热门科技股方向全线退潮，算力硬件方向集体下跌，存储芯片、核电等前期 热门板块同样跌幅居前。 展望后市，德邦证券认为，中美元首会晤完成、中美协议签订将打消市场短期不确定性，未来市场或仍 将震荡上行，建议继续关注科技领域和十五五规划新方向。 热门板块 1、AI应用端走强 影视传媒、游戏、Sora概念等AI应用端集体走强，荣信文化20%涨停，三六零、福石控股等多股涨停。 创新药概念股反弹， ...

Market Overview - The A-share market ended October with all three major indices declining, with the Shanghai Composite Index down 0.81% and a cumulative increase of 1.85% for the month, briefly surpassing 4000 points [1] - The Shenzhen Component Index fell 1.14%, resulting in a cumulative decline of 1.1% for October [1] - The ChiNext Index decreased by 2.31%, with a cumulative drop of 1.56% for the month [1] - The North Stock 50 Index rose by 1.89%, with a cumulative increase of 3.54% in October [1] - Total trading volume in the Shanghai and Shenzhen markets reached 23,498 billion yuan, a decrease of 1,145 billion yuan compared to the previous day [1] - Over 3,700 stocks in the market rose against the trend [1] Sector Performance - The innovative drug, AI data, duty-free shops, film and television, liquor, and battery sectors showed the highest gains [1] - Conversely, the insurance, cultivated diamonds, storage chips, CPO, rare earth permanent magnets, and controllable nuclear fusion sectors experienced the largest declines [1] Notable Stocks - Innovative drug stocks saw a collective surge, with companies like Sanofi, Sihuan Pharmaceutical, and others hitting the daily limit [1] - AI-related stocks, including Fushi Holdings and 360, also experienced significant upward movement [1] - The battery sector remained active, with Tianji Co. achieving two consecutive limit-ups and Enjie Co. hitting the daily limit [1] - Liquor, film and television, and duty-free shop sectors exhibited rotation during the trading session [1] Declining Stocks - Several computing hardware stocks faced adjustments, with Shenghong Technology dropping over 10% [1] - The storage chip sector also retreated, with companies like Lanke Technology and Yunhan Chip City leading the declines [1]

Group 1 - The market continues to show volatility in the afternoon, with storage chips and CPO hardware experiencing a pullback, while sectors such as software, innovative pharmaceuticals, and robotics remain active [1] - As of 14:35, the CSI A500 index has dropped over 1%, and both the ChiNext index and the STAR Market 50 index have fallen more than 2%. However, funds are flowing into related ETFs, with the A500 ETF (E Fund, 159361) seeing net subscriptions exceeding 100 million units, and the ChiNext ETF (159915) reaching net subscriptions of 200 million units [1] - The National Development and Reform Commission has noted that several international economic organizations have raised their forecasts for China's economic growth. For instance, the International Monetary Fund and the World Bank have increased their 2025 growth predictions by 0.8 percentage points compared to their April forecasts [1] Group 2 - Huaxi Securities indicates that the 20th National Congress has solidified long-term policy expectations for investors, combined with expectations of US-China interactions at the APEC summit and potential interest rate cuts by the Federal Reserve, which may boost short-term risk appetite. The "slow bull" market in A-shares is expected to continue, with "big technology" remaining the main theme for the medium to long term [1] - The CSI A500 index consists of 500 stocks with large market capitalization and good liquidity across various industries, balancing "core assets" and "new productive forces." The ChiNext index includes 100 stocks from the ChiNext board with high market capitalization and liquidity, focusing on strategic emerging industries like new energy [2] - The STAR Market 50 index comprises 50 stocks from the STAR Market, with over 65% of its composition in the semiconductor industry. The A500 ETF (E Fund, 159361), ChiNext ETF (159915), and STAR Market 50 ETF (588080) all implement a management fee rate of 0.15% per year, providing investors with diversified investment options [2]

Market Overview - The A-share market experienced a collective decline, with the Shanghai Composite Index down by 0.75%, the Shenzhen Component Index down by 0.76%, and the ChiNext Index down by 1.68% [1] ETF Performance - The Kexin Pharmaceutical ETF (588130) rose by 4.28%, with the latest price at 1.195 yuan and a turnover rate of 13.94% [1] Stock Performance - Among the constituent stocks, three major gainers included: - 3SBio Inc. up by 20.00% - Zai Lab Ltd. up by 15.50% - EdiGene Inc. up by 14.08% - Maiwei Biopharma up by 11.54% - Rongchang Biopharma up by 10.14% - Conversely, the major decliners included: - Haoyuan Pharmaceutical down by 4.80% - Yirui Technology down by 1.59% - Bairen Medical down by 1.14% - Aohua Endoscopy down by 0.59% - Aibot Medical down by 0.40% [1] Investment Recommendations - Guosen Securities suggests focusing on innovative pharmaceutical companies with differentiated innovation capabilities and global commercialization potential, as well as leading CDMO companies with high growth in new and existing orders. - The long-term logic of innovative drugs is favored, with attention on potential bottom reversal targets. - Recommendations also include low-valuation medical device companies that are expected to see performance turning points or acceleration [1]

Core Viewpoint - The innovation drug sector in China is experiencing a significant surge, driven by the introduction of a new commercial insurance innovation drug directory and an acceleration in international business development (BD) activities for domestic innovative drugs [1][4][6]. Group 1: Market Performance - On October 31, A-share innovative drug concept stocks collectively surged, with companies like Sanofi and Shuyou Pharmaceutical hitting a 20% limit up, while others like Zai Lab and Yifang Bio saw increases exceeding 10% [2][3]. - The Hong Kong stock market also showed strength in the innovative drug sector, with companies such as InnoCare and Sanofi Pharmaceutical rising over 11% [2]. Group 2: Policy Changes - The 2025 National Medical Insurance Negotiation commenced on October 30, introducing a "commercial insurance innovation drug directory" mechanism for the first time, which aims to include innovative drugs that are not yet part of the basic medical insurance directory but have high clinical value [4]. - A total of 535 drug names passed the formal review for the basic drug directory, while 121 drug names were approved for the commercial insurance innovation drug directory, indicating a significant focus on high-innovation drugs [4]. Group 3: Business Development Acceleration - Since October, there has been a notable increase in the "outbound" progress of domestic innovative drugs, with several high-profile BD transactions, including a strategic cooperation deal worth up to $11.4 billion between Innovent Biologics and Takeda [6][7]. - As of October 21, 2023, there were 115 outbound licensing agreements for Chinese innovative drugs, totaling $101.24 billion, significantly surpassing the $51.9 billion for the entire year of 2024 [7]. Group 4: Industry Outlook - Analysts indicate that the recent surge in BD transactions reflects China's innovative drug industry entering the global mainstream, transitioning from a focus on generic drugs to becoming a leader in certain areas of innovation [7][8]. - The Chinese pharmaceutical industry has completed a transformation from old to new growth drivers, with innovative drugs opening new growth avenues for companies [8].

Core Viewpoint - The market is shifting its focus from short-term BD to the long-term pipeline value of innovative domestic drugs, particularly those with source innovation capabilities and FIC/BIC product matrices, following data releases from the ESMO conference [1] Group 1: Market Trends - The upcoming National Medical Insurance negotiation in November will determine the speed of new drug hospital adoption, while the December commercial insurance innovation drug catalog may address the issue of high-priced drugs entering hospitals, complementing the medical insurance system [1] - The JP Morgan Healthcare Conference in January is expected to attract global attention, further highlighting the innovative drug sector [1] Group 2: Investment Opportunities - The Guotai Innovation Drug ETF (589720) focuses on innovative drug companies listed on the Sci-Tech Innovation Board, tracking a representative index of 30 high-quality companies, primarily in high-growth biotech [1] - Since the "924 market" last year, the Sci-Tech Innovation Drug Index has outperformed the Hang Seng Hong Kong Stock Connect Innovation Drug Index, with respective gains of 117.04% and 109.62% during the market rebound period from September 24, 2024, to September 30, 2025 [1] - The Sci-Tech Innovation Drug Index may provide better exposure to the resilience of the Sci-Tech Innovation Board when market risk appetite increases [1]